Research Article Details
| Article ID: | A18828 |
| PMID: | 26915720 |
| Source: | Gen Physiol Biophys |
| Title: | Hepatoprotective potential of zingerone against nonalcoholic fatty liver disease in rats fed with fructose-enriched diet. |
| Abstract: | Overconsumption of fructose increases the risk of nonalcoholic fatty liver disease (NAFLD), obesity and metabolic syndrome. NAFLD is currently one of the most common etiologies of chronic liver disease worldwide. The aim of the present study is to evaluate the hepatoprotective potential of zingerone against fructose-enriched diet-induced rat model of nonalcoholic fatty liver disease. Male albino Wistar rats were used and randomly divided into four groups: group 1, control rats fed with standard pellet; group 2, rats were fed normal pellet with intragastric intubation of zingerone (100 mg/kg/day); group 3, rats were fed fructose enriched diet alone; group 4, rats were fed fructose enriched diet with intragastric intubation of zingerone (100 mg/kg/day). Body weight, abdominal circumference, blood glucose, lipid profile and hepatic function indicators were increased and HDL reduced in group 3 rats. Liver pathology of group 3 showed marked changes which includes micro- and macrovesicular steatosis, marked inflammatory cell infiltration, sinusoidal fibrosis and with a significant increase in the area percentage of the collagen. Administration of zingerone reversed the fructose enriched diet induced changes especially body weight, abdominal circumference, blood glucose, lipid profile, hepatic function indicators and restored pathological alteration of liver. Taken together these data provide new insights into the preventive approach of zingerone against the development of the NAFLD. |
| DOI: | 10.4149/gpb_2015041 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |